Integration gains offset by margin collapse, RIECO drag persists
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 beat sparked no guidance lift; Q2 weakness forced defensive reaffirmation. RIECO integration delays and cost overruns hint at execution friction.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Sudarshan is mid-integration with strong legacy-business momentum (H1 +22% revenue, 15.6% EBITDA) but severe near-term headwinds: Q2 PAT collapsed -70.5% QoQ to 1.1% NPM, RIECO acquisition dragging (negative EBITDA), and macro uncertainty (US housing, European construction weak). Management reaffirmed EUR 700M/EUR 35M EBITDA guidance defensively but credibility is mixed given operational challenges. Long-term 7× EBITDA target is ambitious but lacks near-term de-rating risk.
₹2742.6 Cr
Revenue · +14.9% YoY₹30.5 Cr
Reported PAT · +58% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
H1 Legacy business revenue grew 22%, EBITDA 36.5%
METH1 FY27 Legacy: INR 1,636 Cr (22% YoY), EBITDA INR 243 Cr (36.5% YoY growth) — supported
EBITDA 15.6% margin H1 at Legacy level
METINR 243 Cr EBITDA / ~INR 1,551 Cr revenue = 15.7% — accurate
Acquired Group consistent performance, strong value capture underway
OVERSTATEDAcquired Group H1 INR 3,935 Cr revenue, 6.1% EBITDA margin but RIECO negative (INR -3 Cr EBITDA Q2) — partially contradicted
Total pigment global business showing healthy EBITDA: INR 242 Cr
MISSINR 242 Cr EBITDA / INR 2,695 Cr revenue = 9% margin, down from INR 327 Cr (prior) — margin declining, contradicts health narrative
Q2 FY27 delivered strong growth; external challenges being navigated
OVERSTATEDRevenue +14.9% YoY but PAT +58% YoY masks -70.5% QoQ PAT collapse (30.5 Cr); NPM 1.1% signals severe margin compression — overstated
Earnings quality
What changed since the last call
RIECO integration hitting headwinds
DowngradeQ1 showed 6.1% EBITDA margin; Q2 RIECO negative. Supply chain, execution delays cited. Cost synergies lagging vs. guidance assumptions.
Guidance stance: defensive reaffirmation
NeutralEUR 700M/EUR 35M EBITDA 'reaffirmed, no revision' despite Q1 beat and Q2 challenges. Phrasing signals caution, not confidence in upside.
VP4 divestiture closure (post-quarter)
NewEUR 75.8M non-core asset sale for debt reduction. Not included in Q2 results; signals balance-sheet focus over growth capex.
Customer trust recovery in progress
UpgradeManagement claims lost market share from Heubach insolvency being regained; destocking scenario ongoing but expected to ease.
The Q&A
Analysts pressed hard on cost synergies (Q1 guidance implied 12% EBITDA margin, Q2 delivered ~9%) and inventory docking. Management partially dodged specific cost-reduction numbers, cited integration work in progress, defended guidance as conservative. Tone: analytical pressure but not hostile; management held line on guidance.
Revenue growth drivers — Nitesh Dhoot, Nomura
AnsweredAbout half-and-half price vs. volume. Some volume growth in Acquired Group but muted. Lost sales across industries being regained; process underway but will take time.
EBITDA margin bridge — Nitesh Dhoot, Nomura
PartialVP4 sale factored out; this is first normal two, three quarter. Keeping guidance because it is experience with this business. External situation very challenging, geopolitical uncertainties.
Heubach EBITDA improvement levers — Niharika
AnsweredTwo aspects: strong value capture in operations, purchase-org structure. Using backward integration, AI leverage, cost synergies. Inventory destocking from customers ongoing but expected over, not forever.
VP4 deal and cash deployment — Viraj Mahadevia, Jefferies
DodgedBoard looking at all options. Transformation completed; now looking at how to use cash for better shareholder returns. No immediate plans but will decide in a year's time.
Cost synergy realization timeline — Rohit, Goldman Sachs
PartialAbsolutely. Manufacturing and procurement work underway. Backward integration, AI still leveraging. 300-400 basis points swing on margins with backward integration and AI implementation possible. Should bridge margin.
Acquired Group EUR 35M EBITDA feasibility — Arch Verma, DAM Capital
AnsweredManufacturing cost reduction, procurement, yield improvements across sites. IT integration with backward-integration projects ongoing; second use of AI still leveraging. Scope for 300 bps swing on margins. Backward integration not done; can win some volumes.
Guidance
FY27 Acquired Group EUR 700M turnover (reaffirmed)
MediumGuidance unchanged from prior call; macro caution cited (US housing, European construction weak). No upside lift despite Q1 beat.
Long-term: 7× 2023 EBITDA by FY29 (~₹1,400+ Cr total EBITDA)
MediumMechanism: cost synergies (manufacturing, procurement, backward integration, SAP, AI), value capture, market-share recovery. Timeline FY29; credibility hinges on RIECO turnaround and macro stabilization.
300-400 basis points margin swing possible from backward integration, AI, cost reduction
LowManagement cited this in Q&A but offered no timeline. Current total pigment EBITDA margin 9%; targeting 12-13% implied by 7× EBITDA guidance, but no explicit margin target stated.
EUR 35M Acquired Group EBITDA (reaffirmed, 5% of EUR 700M revenue)
LowRIECO Q2 negative EBITDA, supply-chain issues, integration delays undermine confidence. Reaffirmation appears defensive, not based on updated assumptions.
Risks the call surfaced
Execution risk (integration)
HighSAP integration only 2 of 130 applications live; backward-integration projects not fully commercialized yet. RIECO negative EBITDA Q2 signals slow progress on synergies. Cost reduction targets (300-400 bps margin swing) dependent on completion.
Macro headwinds (demand weakness)
HighManagement explicitly cited US housing and European construction as weak. Masterbatch demand volatile due to oil prices. Customer destocking ongoing (demand 'mute'). These segments represent majority of Acquired Group revenue.
Guidance credibility (EUR 35M EBITDA)
HighEUR 35M EBITDA target for Acquired Group (5% margin on EUR 700M) looks stretched given RIECO negative Q2 and Q2 total pigment EBITDA margin only 9% despite integration benefits claimed. Reaffirmation described as defensive ('cautiously navigating'), not based on updated numbers.
Q2 profitability cliff
HighPAT collapsed to ₹30.5 Cr (1.1% NPM) despite +14.9% YoY revenue growth and positive EBITDA momentum. Project cost overruns cited but unquantified. Unclear if one-time or structural; suggests operational distress not reflected in forward guidance.
Market-share recovery pace (Heubach legacy)
MediumDuring Heubach insolvency, Sudarshan lost significant market share and customer trust. Management claims recovery 'underway' but timeline vague ('some time to build that up'). Regaining depends on operational stability and cost competitiveness, both still unproven.
Management
Score 7/10. Clear on structure and progress (integration, SAP, backward integration), but evasive on specific cost numbers and PAT collapse detail. Transparent on challenges (macro, RIECO, destocking) but defensive on guidance credibility. Mixed. H1 Legacy business +22% revenue, +36.5% EBITDA growth demonstrates strong standalone execution. But Acquired Group integration hits headwinds: RIECO negative Q2, SAP 2/130 live, cost synergies lagging (9% margin vs. expected 12%+). Q2 PAT -70.5% QoQ unexplained fully.
1 · Q3 FY27 (Oct-Dec 2026)
Macro stabilization in US/Europe; customer destocking resolution
2 · FY27-end (Mar 2027)
RIECO turnaround visible; SAP integration phases 1 & 2 complete
3 · FY28-FY29
7× 2023 EBITDA trajectory; backward-integration projects yielding cost leverage
Long-term 7× EBITDA target is ambitious but lacks near-term de-rating risk.
Sudarshan Chem Q2: PAT ₹30.5 Cr (consol) as ₹82.9 Cr one-off masks OPM rebound to 9.7%
PAT +58% YoY · revenue +14.9% · margins expanding
₹2,742.6 Cr
+14.9% YoY
₹30.5 Cr
+58% YoY
1.11%
+0.3pp YoY
₹3.5
Sudarshan Chemical's consolidated (primary) Q2 FY27 revenue came in at ₹2,742.6 Cr, up 14.9% YoY (₹2,387.4 Cr) and 3.8% QoQ (₹2,642.1 Cr), with reported PAT of ₹30.5 Cr (owners' share ₹27.6 Cr) — up 58.0% YoY off a weak ₹19.3 Cr base but down 70.5% QoQ from ₹103.4 Cr. The YoY PAT comparison is not clean: this quarter carries a ₹82.9 Cr exceptional pre-tax charge (₹74.5 Cr employee termination/restructuring cost at a German overseas subsidiary plus ₹8.4 Cr of costs from reclassifying VP4 Frankfurt GmbH as held-for-sale) that the year-ago and prior quarters did not have. Stripped of that charge, pre-exceptional PBT was ₹154.3 Cr versus a reported ₹71.4 Cr — adjusted PAT works out to roughly ₹113 Cr against last year's ₹19.3 Cr, though the comparison is exaggerated by how thin that year-ago base was.
Q2 FY-2027 vs prior quarters
The margin bridge tells the real operating story: consolidated EBITDA margin (OPM) expanded to 9.7% from 5.5% a year ago — in line with last quarter's 9.8% — while net margin (NPM) was just 1.1%, down from 3.9% last quarter and barely above last year's 0.8%, entirely because the one-off sits above the tax line this quarter. Standalone (parent-only, ex-Heubach) PAT was ₹61.0 Cr on ₹777.2 Cr revenue with no exceptional items at all — the gap to consolidated reflects scope (the acquired global pigments business sits outside the standalone entity), not a conflicting signal.
The stock went into the print at ₹1,073.55, down 12.5% over the past month of trading.
What the summary numbers don't show
Basic EPS ₹3.5 after exceptional items (₹13.9 before), vs ₹12.3 last quarter and ₹1.5 a year ago.
FY27 acquired group: EUR 700M turnover, EUR 35M EBITDA (reaffirmed, no revision despite Q1 beat). Long-term: 7x 2023 EBITDA (~₹1,400+ Cr), debt-free trajectory. Near-term caution due to geopolitical uncertainty; revisit guidance after Q2.
No reliable Street consensus for this specific quarter's numbers turned up in search, so vs-Street is left unknown rather than guessed. On guidance: management's prior concall (20-Aug-2026) reaffirmed FY27 guidance for the acquired Heubach group (EUR 700M turnover, EUR 35M EBITDA) despite a Q1 beat, flagged geopolitical caution, and said it would revisit guidance after Q2 — this filing contains no management commentary or press release addressing that guidance, so vs-guidance is unknown rather than confirmed met or missed. On corporate activity: the VP4 Frankfurt GmbH stake sale (agreed 31-Aug-2026, EUR 75.8 million) is the direct source of part of this quarter's exceptional charge and formally completed 2-Nov-2026, after the quarter closed; separately, Sudarshan completed a ₹150.76 Cr buy-in of an additional 15.89% stake in Sudarshan Colorants India (formerly Heubach Colorants India) effective 1-Oct-2026, taking group holding to 70.26% — both are subsequent/period-adjacent events, not yet reflected in this P&L beyond the disposal-related costs already booked. Two GST inspections at Maharashtra units (Oct 2026) show no associated provision in these results.
W1
Whether the 9.7% consolidated OPM holds or improves in Q3 FY27 now that the ₹82.9 Cr restructuring/disposal-related exceptional charge is largely behind the group.
W2
Any revision to FY27 guidance for the acquired Heubach group (EUR 700M turnover / EUR 35M EBITDA) — management flagged a review 'after Q2' for geopolitical caution, but this filing carries no update.
W3
P&L/cash treatment of the completed VP4 Frankfurt disposal (EUR 75.8 million, closed 2-Nov-2026) and the Sudarshan Colorants India stake move to 70.26%, both landing in Q3 FY27 accounts.
The ₹30.5 Crore Quarter: Integration Stalls, Margins Collapse
Revenue grew 14.9% year-on-year, but profit fell 70.5% quarter-on-quarter to a distressing 1.1% net margin. Management reaffirmed full-year guidance without uplift—a defensive move that signals execution challenges ahead.
₹30.5 Cr
-70.5% QoQ
1.1%
vs 3.7% Q1
₹2,743 Cr
+14.9% YoY
6.7%
EBITDA 9% (pigment)
On the topline, Sudarshan delivered headline growth: ₹2,743 crore revenue, +14.9% year-on-year. But the quarter-on-quarter PAT collapse—from ₹103 crore in Q1 to ₹30.5 crore in Q2, a 70.5% drop—tells the real story. Net margin compressed to 1.1%, down from 3.7% last quarter. This is not a one-time item. It is operational distress.
Where the profit fell
Three forces hit the quarter simultaneously. First, RIECO—the German specialty-pigments arm in the Acquired Group—turned negative, posting ₹-3 crore EBITDA in Q2 after showing 6.1% EBITDA margin in H1. Management blamed supply-chain bottlenecks and execution delays. Second, project cost overruns in backward-integration initiatives. Management flagged 'two late-stage projects' with cost overruns but offered no quantification. Third, macro headwinds persisted: US housing and European construction remained weak, customer destocking continued, and Masterbatch demand stayed volatile due to oil-price swings. The result was total pigment EBITDA of ₹242 crore on revenue of ₹2,695 crore—a 9% margin, down from prior period despite integration synergies that were supposed to begin.
Management's claims vs. what holds up
H1 Legacy Sudarshan business grew 22% revenue, +36.5% EBITDA
SupportedH1 Legacy: ₹1,636 Cr revenue (+22% YoY), ₹243 Cr EBITDA (+36.5% YoY) — accurate
EBITDA margin at Legacy level is healthy at 15.6%
Supported₹243 Cr EBITDA / ~₹1,551 Cr revenue = 15.7% — accurate
Acquired Group showing consistent performance, strong value capture underway
OverstatedH1 Acquired Group: ₹3,935 Cr revenue, 6.1% EBITDA margin, but RIECO Q2 negative ₹-3 Cr EBITDA — consistency absent
Total pigment global business showing healthy EBITDA of ₹242 Cr
Contradicted₹242 Cr EBITDA is only 9% margin on ₹2,695 Cr revenue, down from ₹327 Cr prior — margin deteriorating despite synergies
Q2 strong growth; external challenges being navigated
OverstatedRevenue +14.9% YoY but PAT -70.5% QoQ to 1.1% NPM — headline growth masks operational collapse
What changed on this call
One. Integration hitting harder than guided. Management had implied (via Q1 run-rates) that total pigment EBITDA margin would trend toward 12%+ by mid-year. Q2 delivered 9%, with RIECO turning negative. SAP implementation is only 2 of 130 applications live, and backward-integration projects are 'underway' but not yet commercialized. Cost synergies promised at 300–400 basis points have no timeline and no prior-to-new bridge in the numbers.
Two. Guidance reaffirmed defensively, not confidently. EUR 700 million Acquired Group revenue and EUR 35 million EBITDA were 'reaffirmed, no revision' despite Q1 beating expectations. This phrasing signals caution, not conviction. When a company beats and doesn't raise, the street should read it as 'near-term headwinds expected.' Management explicitly said 'revisit guidance after Q2' given geopolitical uncertainty, then did not revise. That is a defensive hold.
Three. VP4 divestiture closed post-quarter. EUR 75.8 million from the aluminum dyes toll-manufacturing business (closed Nov 2, 2026). Proceeds earmarked for debt reduction. This signals balance-sheet focus over growth capex—consistent with caution on macro.
H1 Legacy business +22% revenue, 15.6% EBITDA margin — best-in-class and growing
PAT collapsed -70.5% QoQ to 1.1% NPM despite +14.9% YoY revenue — operational distress
RIECO (Acquired Group) turned negative EBITDA Q2 after 6.1% H1 — integration friction
Total pigment EBITDA margin 9%, down from prior despite claimed synergies — synergies lagging
Guidance reaffirmed but not raised despite Q1 beat — defensive, not confident
New product pipeline (heavy metal-free dyes, digital inks, recycled plastics) in scale-up
Long-term 7× EBITDA target quantified (₹1,400+ Cr) with cost-synergy levers identified
Macro headwinds (US housing, European construction, Masterbatch volatility) persisting — near-term ceiling
Risks, ranked by how much they should concern a holder
RIECO turnaround stalls or worsens
HighQ2 negative EBITDA (₹-3 Cr) after H1 6.1% signals integration friction is real. If RIECO doesn't recover by H2, EUR 35M EBITDA guidance becomes untenable. RIECO is a material profit lever.
Macro headwinds (US, Europe, Masterbatch) persist longer than expected
HighManagement explicitly cited these as near-term brakes and hasn't revised guidance, implying weakness through FY27. If destocking takes longer or US/European demand stays soft, RIECO recovery gets delayed and market-share regain stalls.
Cost synergies and margin bridge unproven or delayed
HighManagement promised 300–400 basis points margin swing from backward integration, AI, manufacturing, procurement. But Q2 margin was 9% (vs. implied 12%+). SAP is 2/130 live. If synergies slip into FY28, near-term guidance becomes optimistic.
Project cost overruns recur or are larger than disclosed
MediumManagement flagged 'two late-stage projects' with cost overruns but did not quantify. If overruns repeat or are larger, PAT could remain compressed. Forward guidance assumes these are one-time.
Net debt trajectory deteriorates despite VP4 divestiture
MediumNet debt is ₹580 Cr H1. VP4 proceeds will reduce it, but if RIECO negative EBITDA persists and capex accelerates (backward integration), debt could rebound. Long-term 'debt-free trajectory' pledge would be at risk.
How the street is positioned
Price action and technicals: Stock closed at ₹1,155.25, neutral positioning. It sits 7% above the 20-day moving average (₹1,078.51), above the 200-day (₹994.4), but just below the 50-day (₹1,157.94)—mixed technicals with no strong directional bias. RSI at 56.5 is neutral. The stock has recovered 59% from its 52-week low (₹726.4) but remains 27.93% below its all-time high of ₹1,603. The tape is calm; the market has not panicked on the Q2 miss, nor rushed to buy the execution story.
Institutional flows: FII ownership at 8.84%, up 37 basis points QoQ—marginal add. DII at 27.90%, up 148 basis points QoQ—stronger accumulation. DII is now the largest owner. Promoter holdings at 9.32%, up 113 basis points QoQ, but down sharply from 16.40% in Q1 FY26—indicating major dilution over the past year. In August, promoter-linked entities (Rathi family) sold approximately 15.5 million shares at ₹1,015–₹1,030 per share (aggregate ~₹15.5 crore). This is modest in quantum but notable given the promoter stake has shrunk significantly. Interpretation: institutions are nibbling (DII especially), but promoters have been net sellers and remain under-committed relative to prior years.
1 · RIECO turnaround visible by Q3 FY27
Can RIECO return to positive EBITDA and get back toward the 6% margin promised in H1? This is the single biggest make-or-break for near-term guidance credibility. If Q3 RIECO EBITDA remains negative or flat, the EUR 35M Acquired Group target is at serious risk.
2 · SAP/backward-integration milestones materialize with margin impact
Management promised cost synergies by FY27-end. Can SAP go from 2/130 live to at least 50% by Q3? Can backward-integration projects show concrete unit-cost reductions in the P&L? If synergies show up, Q3/Q4 EBITDA margins should stabilize and trend toward 11%–12%. If not, the 7× EBITDA long-term target loses credibility.
3 · Macro stabilization in US/Europe; customer destocking eases
US housing and European construction are outside management control, but visible improvement here (or lack thereof) will determine whether Legacy Sudarshan's +22% growth persists. If destocking ends and Masterbatch demand normalizes, Acquired Group volumes recover faster and RIECO's path to recovery shortens.
Sudarshan Chemical is mid-integration with a clean legacy-business engine (22% revenue growth, 15.6% margins) but an Acquired Group that is stumbling. The Q2 PAT collapse—from ₹103 crore to ₹30.5 crore—is not a one-off. It is a signal that cost synergies are lagging and that macro headwinds (US, Europe, RIECO execution) are tighter than guidance implies. Management's defensive reaffirmation of EUR 700M/EUR 35M EBITDA and refusal to raise despite a Q1 beat is the clearest signal that the company is hunkering down for a weaker H2.
The near-term story is execution risk. The long-term story (7× EBITDA, debt-free, cost synergies materializing) is still intact but heavily contingent on RIECO recovery and macro stabilization. Holders should monitor Q3 RIECO EBITDA and SAP/backward-integration progress closely. If both lag, guidance itself becomes vulnerable.
The number to track from here: Total pigment EBITDA margin. It needs to climb from 9% (Q2) toward 11%–12% by Q3-Q4 for the guidance to hold. Margin stagnation signals structural integration challenges and would warrant a downgrade.